Press releases

Read more:

Categories

Archive per year

First Tox Study for Nanologica’s Inhalation Platform NLAB Spiro® Completed

Nanologica has completed the first study within the tox program for the inhalation platform NLAB Spiro®. The program now continues with further studies. NLAB Spiro® is Nanologica’s technology platform for inhalation. To validate the safety of the platform, toxicity studies are conducted in several steps and the first study has now been completed. Results from the sub-study are expected to be presented during the third quarter. During the second half of the year, the program

Read more »

Exercise of Rights in Nanologica’s Stock Option Program

In Nanologica’s stock option program 2018/21 exercise of rights in Nanologica’s stock option program has increased the number of shares in the company by 371,346 to 28,165,826 shares. As a result, the share capital increases to SEK 11,548,761. At Nanologica’s Annual General Meeting on May 31, 2018, it was resolved to establish an incentive program of a maximum of 484,883 stock options for the company’s employees. Each option entitles the holder to subscribe for one

Read more »

Nanologica’s patent granted in Australia

The Australian Patent Office has granted Nanologica’s patent titled ”A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery”. The patent protects the company’s technology platform NLAB Spiro® by giving exclusivity on methods for producing particles loaded with active pharmaceutical ingredients for lung delivery, among other dosage forms. ” This patent was granted in Europe last year and it is pleasing that we

Read more »

Nanologica’s CEO sells shares and buys options

CEO Andreas Bhagwani has privately and through his company Vega Bianca AB divested 323,000 shares in Nanologica AB for private economic reasons. At the same time, he exercised 227,566 options to shares. Following the transactions, Andreas Bhagwani’s holdings in Nanologica AB amounts to 2,019,764 shares, equivalent to 7.3 percent of the total number of shares in Nanologica, and 165,000 options. “The sale is made for personal economic reasons. Nanologica remains my largest investment and commitment,

Read more »

Nanologica Recruits VP Drug Development

Nanologica has recruited Ulf Ericsson as VP Drug Development as part of the strategy to enhance focus on the respiratory field and inhalation, within the business area Drug Development. Mr. Ericsson will be responsible for leading the work on developing inhalable pharmaceuticals.     To accelerate the development of the NLAB Spiro® inhalation platform, Ulf Ericsson has been recruited as VP Drug Development. The position includes leading efforts and strategy for the development and commercialization of

Read more »

Kommuniké från årsstämma i Nanologica AB

Nanologica AB (publ) (”Bolaget”) höll idag den 27 maj 2021 sin årsstämma för verksamhetsåret 2020, varvid besluten nedan fattades. Stämman hölls som en s.k. poströstningsstämma och något fysiskt stämmomöte hölls således inte. För mer detaljerad information om innehållet i besluten hänvisas till den fullständiga kallelsen till årsstämman. Kallelse till årsstämma samt fullständiga förslag finns tillgängliga på Bolagets webbplats, www.nanologica.com. Protokoll från årsstämman kommer att tillhandahållas på nämnda webbplats inom två veckor från dagen för stämman.

Read more »